Enanta Pharmaceuticals (ENTA) reported Monday positive topline results from a phase 2 study evaluating zelicapavir in children with respiratory syncytial virus.
The company said zelicapavir showed a significant antiviral effect in young children with respiratory syncytial virus and that the experimental drug reduced viral loads in both hospitalized and non-hospitalized infants compared to placebo.
The drug was also well-tolerated and had a favorable safety profile, Enata added.
Shares of the company were down 2.6% in recent trading.
Price: 7.79, Change: -0.21, Percent Change: -2.63
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.